Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors
Giuseppe Campiani, Caterina Cavella, J.D. Osko, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 14, pp. 9960-9988
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis
Xiaohui Miao, Pan Liu, Yangyang Liu, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117463-117463
Closed Access | Times Cited: 2
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option
Martina Korfei, Poornima Mahavadi, Andreas Guenther
Cells (2022) Vol. 11, Iss. 10, pp. 1626-1626
Open Access | Times Cited: 45
Difluoromethyl-1,3,4-oxadiazoles Are Selective, Mechanism-Based, and Essentially Irreversible Inhibitors of Histone Deacetylase 6
Beate König, P. R. Watson, Nina Reßing, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 19, pp. 13821-13837
Open Access | Times Cited: 24
Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases
D.W. Christianson
Accounts of Chemical Research (2024) Vol. 57, Iss. 8, pp. 1135-1148
Closed Access | Times Cited: 11
Groebke Blackburn Bienaymé-mediated multi-component synthesis of selective HDAC6 inhibitors with anti-inflammatory properties
Fabian B. Kraft, Jana Enns, Irina Honin, et al.
Bioorganic Chemistry (2024) Vol. 143, pp. 107072-107072
Closed Access | Times Cited: 8
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors
Anna Fontana, Ilaria Cursaro, Gabriele Carullo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 17, pp. 10014-10014
Open Access | Times Cited: 29
Discovery of HDAC6, HDAC8, and 6/8 Inhibitors and Development of Cell-Based Drug Screening Models for the Treatment of TGF-β-Induced Idiopathic Pulmonary Fibrosis
Wei-Chieh Yu, T.Y. Yeh, Chih-Hung Ye, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10528-10557
Closed Access | Times Cited: 15
Nutritionally enriched tomatoes (Solanum lycopersicum L.) grown with wood distillate: chemical and biological characterization for quality assessment
Riccardo Fedeli, Ludovica Marotta, Luca Frattaruolo, et al.
Journal of Food Science (2023) Vol. 88, Iss. 12, pp. 5324-5338
Open Access | Times Cited: 14
Discovery of novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors for the efficient treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo
Yanchun Li, Huali Yang, Xiangling Zhao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116608-116608
Closed Access | Times Cited: 5
Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis
Haipeng Cheng, Shi-he Jiang, Jin Cai, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 5
Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability
Stefano Federico, Tuhina Khan, Anna Fontana, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114409-114409
Closed Access | Times Cited: 19
Discovery of novel selective HDAC6 inhibitors via a scaffold hopping approach for the treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo
Jishun Quan, Ma Chao, Xianchen Zhao, et al.
Bioorganic Chemistry (2025) Vol. 159, pp. 108360-108360
Closed Access
Challenging Triple Negative Breast Cancer through HDAC6 selective inhibition: novel cap-group identification, structure-activity relationships, computational and biological studies
Simona Barone, Ivana Bello, A Guadagni, et al.
European Journal of Medicinal Chemistry (2025) Vol. 292, pp. 117634-117634
Open Access
Epigenetic hallmarks in pulmonary fibrosis: New advances and perspectives
Yun-Sen Zhang, Bin Tu, Kai Song, et al.
Cellular Signalling (2023) Vol. 110, pp. 110842-110842
Closed Access | Times Cited: 10
The landscape of histone modification in organ fibrosis
Jun-Bo You, Yi Cao, Qing-Ye You, et al.
European Journal of Pharmacology (2024) Vol. 977, pp. 176748-176748
Closed Access | Times Cited: 3
Targeting Relevant HDACs to Support the Survival of Cone Photoreceptors in Inherited Retinal Diseases: Identification of a Potent Pharmacological Tool with In Vitro and In Vivo Efficacy
Gabriele Carullo, Noemi Orsini, Ilaria Piano, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 17, pp. 14946-14973
Closed Access | Times Cited: 3
Synthesis and photodynamic activity of new 5‐[(E)‐2‐(3‐alkoxy‐1‐phenyl‐1H‐pyrazol‐4‐yl)ethenyl]‐2‐phenyl‐3H‐indoles
Gabrielė Varvuolytė, Eva Řezníčková, Aurimas Bieliauskas, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Open Access | Times Cited: 3
HDAC6 promotes inflammation in lupus nephritis mice by regulating transcription factors MAFF and KLF5 in renal fibrosis
Meihui Deng, Xiao Tan, Xiaojie Peng, et al.
Renal Failure (2024) Vol. 46, Iss. 2
Open Access | Times Cited: 3
Novel Labdane Diterpenes-Based Synthetic Derivatives: Identification of a Bifunctional Vasodilator That Inhibits CaV1.2 and Stimulates KCa1.1 Channels
Gabriele Carullo, Simona Saponara, Amer Ahmed, et al.
Marine Drugs (2022) Vol. 20, Iss. 8, pp. 515-515
Open Access | Times Cited: 16
Discovery of novel benzohydroxamate-based histone deacetylase 6 (HDAC6) inhibitors with the ability to potentiate anti-PD-L1 immunotherapy in melanoma
Xiaopeng Peng, Ziwen Yu, Goverdhan Surineni, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 9
N-(2-Aminophenyl)-benzamide Inhibitors of Class I HDAC Enzymes with Antiproliferative and Antifibrotic Activity
Dimitrios Triantafyllos Gerokonstantis, Christiana Mantzourani, Dimitrios Gkikas, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14357-14376
Closed Access | Times Cited: 8
Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology
Simona Barone, E Cassese, Antonella Ilenia Alfano, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 4, pp. 3080-3097
Open Access | Times Cited: 14
Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosis
Manas Sehgal, Sharayu Manish Jakhete, Amruta Ganesh Manekar, et al.
Heliyon (2022) Vol. 8, Iss. 8, pp. e09773-e09773
Open Access | Times Cited: 14
Aberrant expression of histone deacetylase 8 in endometriosis and its potential as a therapeutic target
Hanxi Zheng, Xishi Liu, Sun‐Wei Guo
Reproductive Medicine and Biology (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 7
Pioneering first‐in‐class FAAH‐HDAC inhibitors as potential multitarget neuroprotective agents
Alessandro Papa, Ilaria Cursaro, Luca Pozzetti, et al.
Archiv der Pharmazie (2023) Vol. 356, Iss. 12
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top